Vimentin diversity in health and disease

Cells

Volumn 7, Issue 10, 2018, Pages

  Danielsson, Frida ^a   Peterson, McKenzie Kirsten ^b   Araújo, Helena Caldeira ^c   Lautenschläger, Franziska ^d   Gad, Annica Karin Britt ^c,e  

^a ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MADEIRA   (Portugal)

^d SAARLAND UNIVERSITY   (Germany)

^e UPPSALA UNIVERSITY   (Sweden)

Author keywords

Biomechanics; Cancer and metastasis; Cell mechanical stiffness or elasticity; Cell extracellular matrix adhesions; Cellular contractility; Clinical biomarkers; Drug target; Epithelial mesenchymal transition; Extracellular vimentin; Intermediate filaments; Tissue regeneration; Vimentin

Indexed keywords

ACTIN; BIOLOGICAL MARKER; DESMIN; FLUINDOSTATIN; GLIAL FIBRILLARY ACIDIC PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 12; INTERMEDIATE FILAMENT PROTEIN; MESSENGER RNA; MICRORNA; MONOCLONAL ANTIBODY; PERIPHERIN; SILIBININ; SIMVASTATIN; VIMENTIN; WITHAFERIN A;

AGING; AMINO ACID SEQUENCE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ATHEROSCLEROSIS; CATARACT; CELL PROLIFERATION; CELLULAR, SUBCELLULAR AND MOLECULAR BIOLOGICAL PHENOMENA AND FUNCTIONS; CROHN DISEASE; DIABETES MELLITUS; ELECTRON SPIN RESONANCE; ESOPHAGEAL SQUAMOUS CELL CARCINOMA CELL LINE; GENE EXPRESSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOHISTOCHEMISTRY; MELANOMA; METASTASIS; MYOPATHY; NONHUMAN; POLYMERIZATION; PROTEIN ASSEMBLY; PROTEIN SECONDARY STRUCTURE; PROTEIN TERTIARY STRUCTURE; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; X RAY CRYSTALLOGRAPHY;

EID: 85117876789     PISSN: None     EISSN: 20734409     Source Type: Journal    
DOI: 10.3390/cells7100147     Document Type: Review

References (325)

1. Schaffeld, M.; Herrmann, H.; Schultess, J.; Markl, J. Vimentin and desmin of a cartilaginous fish, the shark Scyliorhinus stellaris: Sequence, expression patterns and in vitro assembly. Eur. J. Cell Biol. 2001, 80, 692–702. [CrossRef] [PubMed]
2. Muller, M.; Bhattacharya, S.S.; Moore, T.; Prescott, Q.; Wedig, T.; Herrmann, H.; Magin, T.M. Dominant cataract formation in association with a vimentin assembly disrupting mutation. Hum. Mol. Genet. 2009, 18, 1052–1057. [CrossRef] [PubMed]
3. Satelli, A.; Li, S. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell. Mol. Life Sci. CMLS 2011, 68, 3033–3046. [CrossRef] [PubMed]
4. Henderson, P.; Wilson, D.C.; Satsangi, J.; Stevens, C. A role for vimentin in Crohn disease. Autophagy 2014, 8, 1695–1696. [CrossRef] [PubMed]
5. Fernández-Ortega, C.; Ramírez, A.; Casillas, D.; Paneque, T.; Ubieta, R.; Dubed, M.; Navea, L.; Castellanos-Serra, L.; Duarte, C.; Falcon, V.; et al. Identification of Vimentin as a Potential Therapeutic Target against HIV Infection. Viruses 2016, 8, 98. [CrossRef] [PubMed]
6. Chang, L.; Goldman, R.D. Intermediate filaments mediate cytoskeletal crosstalk. Nat. Rev. Mol. Cell Biol. 2004, 5, 601–613. [CrossRef] [PubMed]
7. Robert, A.; Hookway, C.; Gelfand, V.I. Intermediate filament dynamics: What we can see now and why it matters. BioEssays 2016, 38, 232–243. [CrossRef] [PubMed]
8. Lowery, J.; Kuczmarski, E.R.; Herrmann, H.; Goldman, R.D. Intermediate Filaments Play a Pivotal Role in Regulating Cell Architecture and Function. J. Biol. Chem. 2015, 290, 17145–17153. [CrossRef] [PubMed]
9. Ivaska, J.; Pallari, H.-M.; Nevo, J.; Eriksson, J.E. Novel functions of vimentin in cell adhesion, migration, and signaling. Exp. Cell Res. 2007, 313, 2050–2062. [CrossRef] [PubMed]
10. Minin, A.A.; Moldaver, M.V. Intermediate vimentin filaments and their role in intracellular organelle distribution. Biochemistry 2008, 73, 1453–1466. [CrossRef] [PubMed]
11. Dave, J.M.; Bayless, K.J. Vimentin as an Integral Regulator of Cell Adhesion and Endothelial Sprouting. Microcirculation 2014, 21, 333–344. [CrossRef] [PubMed]
12. Schweitzer, S.C.; Evans, R.M. Vimentin and lipid metabolism. Sub-Cell. Biochem. 1998, 31, 437–462.
13. Etienne-Manneville, S. Cytoplasmic Intermediate Filaments in Cell Biology. Annu. Rev. Cell Dev. Biol. 2018, 34. [CrossRef] [PubMed]
14. Parry, D.A.D.; Strelkov, S.V.; Burkhard, P.; Aebi, U.; Herrmann, H. Towards a molecular description of intermediate filament structure and assembly. Exp. Cell Res. 2007, 313, 2204–2216. [CrossRef] [PubMed]
15. Wang, N.; Stamenovic, D. Mechanics of vimentin intermediate filaments. In Mechanics of Elastic Biomolecules; Springer: Dordrecht, The Netherlands, 2003; pp. 535–540.
16. Herrmann, H.; Aebi, U. Intermediate Filaments: Structure and Assembly. Cold Spring Harb. Perspect. Biol. 2016, 8, a018242. [CrossRef] [PubMed]
17. Pekny, M. Astrocytic intermediate filaments: Lessons from GFAP and vimentin knock-out mice. In Glial Cell Function; Elsevier: New York, NY, USA, 2001; pp. 23–30.
18. Kidd, M.E.; Shumaker, D.K.; Ridge, K.M. The role of vimentin intermediate filaments in the progression of lung cancer. Am. J. Respir. Cell Mol. Biol. 2014, 50, 1–6. [CrossRef] [PubMed]
19. Lazarova, D.L.; Bordonaro, M. Vimentin, colon cancer progression and resistance to butyrate and other HDACis. J. Cell. Mol. Med. 2016, 20, 989–993. [CrossRef] [PubMed]
20. Buckley, I.K.; Porter, K.R. Cytoplasmic fibrils in living cultured cells. Protoplasma 1967, 64, 349–380. [CrossRef] [PubMed]
21. Small, J.V.; Sobieszek, A. Studies on the function and composition of the 10-NM(100-A) filaments of vertebrate smooth muscle. J. Cell Sci. 1977, 23, 243–268. [PubMed]
22. Hynes, R.O.; Destree, A.T. 10 nm filaments in normal and transformed cells. Cell 1978, 13, 151–163. [CrossRef]
23. Franke, W.W.; Schmid, E.; Osborn, M.; Weber, K. Different intermediate-sized filaments distinguished by immunofluorescence microscopy. Proc. Natl. Acad. Sci. USA 1978, 75, 5034–5038. [CrossRef] [PubMed]
24. Herrmann, H.; Aebi, U. Intermediate filaments and their associates: Multi-talented structural elements specifying cytoarchitecture and cytodynamics. Curr. Opin. Cell Biol. 2000, 12, 79–90. [CrossRef]
25. Conway, J.F.; Parry, D.A.D. Intermediate filament structure: 3. Analysis of sequence homologies. Int. J. Biol. Macromol. 1988, 10, 79–98. [CrossRef]
26. Quax, W.; Egberts, W.V.; Hendriks, W.; Quax-Jeuken, Y.; Bloemendal, H. The structure of the vimentin gene. Cell 1983, 35, 215–223. [CrossRef]
27. Quax-Jeuken, Y.E.; Quax, W.J.; Bloemendal, H. Primary and secondary structure of hamster vimentin predicted from the nucleotide sequence. Proc. Natl. Acad. Sci. USA 1983, 80, 3548–3552. [CrossRef] [PubMed]
28. Bloemendal, H.; Quax, W.; Quax-Jeuken, Y.; Dodemont, H.; Ramaekers, F.; Dunia, I.; Benedetti, L. Organization and expression of the vimentin gene. Mol. Biol. Rep. 1983, 9, 115–118. [CrossRef] [PubMed]
29. Zehner, Z.E.; Paterson, B.M. Characterization of the chicken vimentin gene: Single copy gene producing multiple mRNAs. Proc. Natl. Acad. Sci. USA 1983, 80, 911–915. [CrossRef] [PubMed]
30. Capetanaki, Y.G.; Ngai, J.; Flytzanis, C.N.; Lazarides, E. Tissue-specific expression of two mRNA species transcribed from a single vimentin gene. Cell 1983, 35, 411–420. [CrossRef]
31. Quax, W.; Meera Khan, P.; Quax-Jeuken, Y.; Bloemendal, H. The human desmin and vimentin genes are located on different chromosomes. Gene 1985, 38, 189–196. [CrossRef]
32. Perreau, J.; Lilienbaum, A.; Vasseur, M.; Paulin, D. Nucleotide sequence of the human vimentin gene and regulation of its transcription in tissues and cultured cells. Gene 1988, 62, 7–16. [CrossRef]
33. Sommers, C.L.; Walker-Jones, D.; Heckford, S.E.; Worland, P.; Valverius, E.; Clark, R.; McCormick, F.; Stampfer, M.; Abularach, S.; Gelmann, E.P. Vimentin rather than keratin expression in some hormone-independent breast cancer cell lines and in oncogene-transformed mammary epithelial cells. Cancer Res. 1989, 49, 4258–4263. [PubMed]
34. Herrmann, H.; Aebi, U. Intermediate filaments: Molecular structure, assembly mechanism, and integration into functionally distinct intracellular Scaffolds. Annu. Rev. Biochem. 2004, 73, 749–789. [CrossRef] [PubMed]
35. Parry, D.A.D. Hendecad repeat in segment 2A and linker L2 of intermediate filament chains implies the possibility of a right-handed coiled-coil structure. J. Struct. Biol. 2006, 155, 370–374. [CrossRef] [PubMed]
36. Chernyatina, A.A.; Guzenko, D.; Strelkov, S.V. Intermediate filament structure: The bottom-up approach. Curr. Opin. Cell Biol. 2015, 32, 65–72. [CrossRef] [PubMed]
37. Chernyatina, A.A.; Nicolet, S.; Aebi, U.; Herrmann, H.; Strelkov, S.V. Atomic structure of the vimentin central α-helical domain and its implications for intermediate filament assembly. Proc. Natl. Acad. Sci. USA 2012, 109, 13620–13625. [CrossRef] [PubMed]
38. Aziz, A.; Hess, J.F.; Budamagunta, M.S.; Voss, J.C.; Kuzin, A.P.; Huang, Y.J.; Xiao, R.; Montelione, G.T.; FitzGerald, P.G.; Hunt, J.F. The structure of vimentin linker 1 and rod 1B domains characterized by site-directed spin-labeling electron paramagnetic resonance (SDSL-EPR) and X-ray crystallography. J. Biol. Chem. 2012, 287, 28349–28361. [CrossRef] [PubMed]
39. Premchandar, A.; Mücke, N.; Poznański, J.; Wedig, T.; Kaus-Drobek, M.; Herrmann, H.; Dadlez, M. Structural Dynamics of the Vimentin Coiled-coil Contact Regions Involved in Filament Assembly as Revealed by Hydrogen-Deuterium Exchange. J. Biol. Chem. 2016, 291, 24931–24950. [CrossRef] [PubMed]
40. Blumenberg, M. Evolution of homologous domains of cytoplasmic intermediate filament proteins and lamins. Mol. Biol. Evol. 1989, 6, 53–65. [PubMed]
41. Robert, A.; Rossow, M.J.; Hookway, C.; Adam, S.A.; Gelfand, V.I. Vimentin filament precursors exchange subunits in an ATP-dependent manner. Proc. Natl. Acad. Sci. USA 2015, 112, E3505–E3514. [CrossRef] [PubMed]
42. Aziz, A.; Hess, J.F.; Budamagunta, M.S.; FitzGerald, P.G.; Voss, J.C. Head and Rod 1 Interactions in Vimentin Identification of contact sites, structure, and changes with phosphorylation using site-directed spin labeling and electron paramagnetic resonance. J. Biol. Chem. 2009, 284, 7330–7338. [CrossRef] [PubMed]
43. Herrmann, H.; Häner, M.; Brettel, M.; Müller, S.A.; Goldie, K.N.; Fedtke, B.; Lustig, A.; Franke, W.W.; Aebi, U. Structure and assembly properties of the intermediate filament protein vimentin: The role of its head, rod and tail domains. J. Mol. Biol. 1996, 264, 933–953. [CrossRef] [PubMed]
44. Steven, A.C.; Hainfeld, J.F.; Trus, B.L.; Wall, J.S.; Steinert, P.M. The distribution of mass in heteropolymer intermediate filaments assembled in vitro. Stem analysis of vimentin/desmin and bovine epidermal keratin. J. Biol. Chem. 1983, 258, 8323–8329. [PubMed]
45. Soellner, P.; Quinlan, R.A.; Franke, W.W. Identification of a distinct soluble subunit of an intermediate filament protein: Tetrameric vimentin from living cells. Proc. Natl. Acad. Sci. USA 1985, 82, 7929–7933. [CrossRef] [PubMed]
46. Nöding, B.; Herrmann, H.; Köster, S. Direct observation of subunit exchange along mature vimentin intermediate filaments. Biophys. J. 2014, 107, 2923–2931. [CrossRef] [PubMed]
47. Herrmann, H.; Häner, M.; Brettel, M.; Ku, N.O.; Aebi, U. Characterization of distinct early assembly units of different intermediate filament proteins. J. Mol. Biol. 1999, 286, 1403–1420. [CrossRef] [PubMed]
48. Georgakopoulou, S.; Möller, D.; Sachs, N.; Herrmann, H.; Aebi, U. Near-UV circular dichroism reveals structural transitions of vimentin subunits during intermediate filament assembly. J. Mol. Biol. 2009, 386, 544–553. [CrossRef] [PubMed]
49. Geisler, N.; Weber, K. Comparison of the proteins of two immunologically distinct intermediate-sized filaments by amino acid sequence analysis: Desmin and vimentin. Proc. Natl. Acad. Sci. USA 1981, 78, 4120–4123. [CrossRef] [PubMed]
50. Geisler, N. Proteinchemical characterization of three structurally distinct domains along the protofilament unit of desmin 10 nm filaments. Cell 1982, 30, 277–286. [CrossRef]
51. Steinert, P.M.; Steven, A.C.; Roop, D.R. The molecular biology of intermediate filaments. Cell 1985, 42, 411–420. [CrossRef]
52. Conway, J.F.; Parry, D.A. Structural features in the heptad substructure and longer range repeats of two-stranded alpha-fibrous proteins. Int. J. Biol. Macromol. 1990, 12, 328–334. [CrossRef]
53. Parry, D.A.D.; Fraser, R.D.B.; Squire, J.M. Fifty years of coiled-coils and α-helical bundles: A close relationship between sequence and structure. J. Struct. Biol. 2008, 163, 258–269. [CrossRef] [PubMed]
54. Colakoğlu, G.; Brown, A. Intermediate filaments exchange subunits along their length and elongate by end-to-end annealing. J. Cell Biol. 2009, 185, 769–777. [CrossRef] [PubMed]
55. Herrmann, H.; Bär, H.; Kreplak, L.; Strelkov, S.V.; Aebi, U. Intermediate filaments: From cell architecture to nanomechanics. Nat. Rev. Mol. Cell Biol. 2007, 8, 562–573. [CrossRef] [PubMed]
56. Plodinec, M.; Loparic, M.; Suetterlin, R.; Herrmann, H.; Aebi, U.; Schoenenberger, C.-A. The nanomechanical properties of rat fibroblasts are modulated by interfering with the vimentin intermediate filament system. J. Struct. Biol. 2011, 174, 476–484. [CrossRef] [PubMed]
57. Wickert, U.; Mücke, N.; Wedig, T.; Müller, S.A.; Aebi, U.; Herrmann, H. Characterization of the in vitro co-assembly process of the intermediate filament proteins vimentin and desmin: Mixed polymers at all stages of assembly. Eur. J. Cell Biol. 2005, 84, 379–391. [CrossRef] [PubMed]
58. Snider, N.T.; Omary, M.B. Post-translational modifications of intermediate filament proteins: Mechanisms and functions. Nat. Rev. Mol. Cell Biol. 2014, 15, 163–177. [CrossRef] [PubMed]
59. Shi, A.-M.; Tao, Z.-Q.; Li, R.; Wang, Y.-Q.; Wang, X.; Zhao, J. Vimentin and post-translational modifications in cell motility during cancer—A review. Eur. Rev. Med. Pharmacol. Sci. 2016, 20, 2603–2606. [PubMed]
60. Bouamrani, A.; Ramus, C.; Gay, E.; Pelletier, L.; Cubizolles, M.; Brugière, S.; Wion, D.; Berger, F.; Issartel, J.-P. Increased Phosphorylation of Vimentin in Noninfiltrative Meningiomas. PLoS ONE 2010, 5, e9238. [CrossRef] [PubMed]
61. Wang, L.; Zhang, J.; Banerjee, S.; Barnes, L.; Sajja, V.; Liu, Y.; Guo, B.; Du, Y.; Agarwal, M.K.; Wald, D.N.; et al. Sumoylation of Vimentin354 Is Associated with PIAS3 Inhibition of Glioma Cell Migration. Oncotarget 2010, 1, 620–627. [PubMed]
62. Choudhary, C.; Kumar, C.; Gnad, F.; Nielsen, M.L.; Rehman, M.; Walther, T.C.; Olsen, J.V.; Mann, M. Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions. Science 2009, 325, 834–840. [CrossRef] [PubMed]
63. Slawson, C.; Lakshmanan, T.; Knapp, S.; Hart, G.W. A Mitotic GlcNAcylation/Phosphorylation Signaling Complex Alters the Posttranslational State of the Cytoskeletal Protein Vimentin. Mol. Biol. Cell 2008, 19, 4130–4140. [CrossRef] [PubMed]
64. Kueper, T.; Grune, T.; Prahl, S.; Lenz, H.; Welge, V.; Biernoth, T.; Vogt, Y.; Muhr, G.-M.; Gaemlich, A.; Jung, T.; et al. Vimentin is the specific target in skin glycation. Structural prerequisites, functional consequences, and role in skin aging. J. Biol. Chem. 2007, 282, 23427–23436. [CrossRef] [PubMed]
65. Zhu, Y.; Zhang, Y.; Sui, Z.; Zhang, Y.; Liu, M.; Tang, H. USP14 de-ubiquitinates vimentin and miR-320a modulates USP14 and vimentin to contribute to malignancy in gastric cancer cells. Oncotarget 2016, 8, 48725–48736. [CrossRef] [PubMed]
66. Tarbet, H.J.; Dolat, L.; Smith, T.J.; Condon, B.M.; O’Brien, E.T.; Valdivia, R.H.; Boyce, M. Site-specific glycosylation regulates the form and function of the intermediate filament cytoskeleton. eLife 2018, 7, 560. [CrossRef] [PubMed]
67. Goto, H.; Tanabe, K.; Manser, E.; Lim, L.; Yasui, Y.; Inagaki, M. Phosphorylation and reorganization of vimentin by p21-activated kinase (PAK). Genes Cells 2002, 7, 91–97. [CrossRef] [PubMed]
68. Sihag, R.K.; Inagaki, M.; Yamaguchi, T.; Shea, T.B.; Pant, H.C. Role of phosphorylation on the structural dynamics and function of types III and IV intermediate filaments. Exp. Cell Res. 2007, 313, 2098–2109. [CrossRef] [PubMed]
69. Eriksson, J.E.; He, T.; Trejo-Skalli, A.V.; Härmälä-Braskén, A.-S.; Hellman, J.; Chou, Y.-H.; Goldman, R.D. Specific in vivo phosphorylation sites determine the assembly dynamics of vimentin intermediate filaments. J. Cell Sci. 2004, 117, 919–932. [CrossRef] [PubMed]
70. Hyder, C.L.; Pallari, H.-M.; Kochin, V.; Eriksson, J.E. Providing cellular signposts–post-translational modifications of intermediate filaments. FEBS Lett. 2008, 582, 2140–2148. [CrossRef] [PubMed]
71. Zhu, Q.-S.; Rosenblatt, K.; Huang, K.-L.; Lahat, G.; Brobey, R.; Bolshakov, S.; Nguyen, T.; Ding, Z.; Belousov, R.; Bill, K.; et al. Vimentin is a novel AKT1 target mediating motility and invasion. Oncogene 2011, 30, 457–470. [CrossRef] [PubMed]
72. Nicholl, I.D.; Quinlan, R.A. Chaperone activity of alpha-crystallins modulates intermediate filament assembly. EMBO J. 1994, 13, 945–953. [CrossRef] [PubMed]
73. Song, S.; Hanson, M.J.; Liu, B.-F.; Chylack, L.T.; Liang, J.J.-N. Protein-protein interactions between lens vimentin and alphaB-crystallin using FRET acceptor photobleaching. Mol. Vis. 2008, 14, 1282–1287. [PubMed]
74. Yamamoto, Y.; Irie, K.; Kurihara, H.; Sakai, T.; Takai, Y. Vmac: A novel protein associated with vimentin-type intermediate filament in podocytes of rat kidney. Biochem. Biophys. Res. Commun. 2004, 315, 1120–1125. [CrossRef] [PubMed]
75. Thul, P.J.; ÅAkesson, L.; Wiking, M.; Mahdessian, D.; Geladaki, A.; Ait Blal, H.; Alm, T.; Asplund, A.; Björk, L.; Breckels, L.M.; et al. A subcellular map of the human proteome. Science 2017, 356, eaal3321. [CrossRef] [PubMed]
76. Ramaekers, F.C.; Dunia, I.; Dodemont, H.J.; Benedetti, E.L.; Bloemendal, H. Lenticular intermediate-sized filaments: Biosynthesis and interaction with plasma membrane. Proc. Natl. Acad. Sci. USA 1982, 79, 3208–3212. [CrossRef] [PubMed]
77. Ramaekers, F.C.; Poels, L.G.; Jap, P.H.; Bloemendal, H. Simultaneous demonstration of microfilaments and intermediate-sized filaments in the lens by double immunofluorescence. Exp. Eye Res. 1982, 35, 363–369. [CrossRef]
78. Schnitzer, J.; Franke, W.W.; Schachner, M. Immunocytochemical demonstration of vimentin in astrocytes and ependymal cells of developing and adult mouse nervous system. J. Cell Biol. 1981, 90, 435–447. [CrossRef] [PubMed]
79. Tapscott, S.J.; Bennett, G.S.; Toyama, Y.; Kleinbart, F.; Holtzer, H. Intermediate filament proteins in the developing chick spinal cord. Dev. Biol. 1981, 86, 40–54. [CrossRef]
80. Sax, C.M.; Farrell, F.X.; Zehner, Z.E. Down-regulation of vimentin gene expression during myogenesis is controlled by a 5’-flanking sequence. Gene 1989, 78, 235–242. [CrossRef]
81. Uhlén, M.; Fagerberg, L.; Hallström, B.M.; Lindskog, C.; Oksvold, P.; Mardinoglu, A.; Sivertsson, A.; Kampf, C.; Sjöstedt, E.; Asplund, A.; et al. Tissue-based map of the human proteome. Science 2015, 347, 1260419. [CrossRef] [PubMed]
82. GTEx Consortium. Genetic effects on gene expression across human tissues. Nature 2017, 550, 204–213. [CrossRef] [PubMed]
83. The FANTOM Consortium and the RIKEN PMI and CLST (DGT). A promoter-level mammalian expression atlas. Nature 2014, 507, 462–470. [CrossRef] [PubMed]
84. Prahlad, V.; Yoon, M.; Moir, R.D.; Vale, R.D.; Goldman, R.D. Rapid Movements of Vimentin on Microtubule Tracks: Kinesin-dependent Assembly of Intermediate Filament Networks. J. Cell Biol. 1998, 143, 159–170. [CrossRef] [PubMed]
85. Robert, A.; Herrmann, H.; Davidson, M.W.; Gelfand, V.I. Microtubule-dependent transport of vimentin filament precursors is regulated by actin and by the concerted action of Rho-and p21-activated kinases. FASEB J. 2014, 28, 2879–2890. [CrossRef] [PubMed]
86. Leduc, C.; Etienne-Manneville, S. Regulation of microtubule-associated motors drives intermediate filament network polarization. J. Cell Biol. 2017, 216, 1689–1703. [CrossRef] [PubMed]
87. Valgeirsdóttir, S.; Claesson-Welsh, L.; Bongcam-Rudloff, E.; Hellman, U.; Westermark, B.; Heldin, C.H. PDGF induces reorganization of vimentin filaments. J. Cell Sci. 1998, 111 Pt 14, 1973–1980.
88. Rathje, L.-S.Z.; Nordgren, N.; Pettersson, T.; Rönnlund, D.; Widengren, J.; Aspenström, P.; Gad, A.K.B. Oncogenes induce a vimentin filament collapse mediated by HDAC6 that is linked to cell stiffness. Proc. Natl. Acad. Sci. USA 2014, 111, 1515–1520. [CrossRef] [PubMed]
89. Inagaki, M.; Nishi, Y.; Nishizawa, K.; Matsuyama, M.; Sato, C. Site-specific phosphorylation induces disassembly of vimentin filaments in vitro. Nature 1987, 328, 649–652. [CrossRef] [PubMed]
90. Inagaki, M.; Gonda, Y.; Ando, S.; Kitamura, S.; Nishi, Y.; Sato, C. Regulation of assembly-disassembly of intermediate filaments in vitro. Cell Struct. Funct. 1989, 14, 279–286. [CrossRef] [PubMed]
91. Colucci-Guyon, E.; Portier, M.-M.; Dunia, I.; Paulin, D.; Pournin, S.; Babinet, C. Mice lacking vimentin develop and reproduce without an obvious phenotype. Cell 1994, 79, 679–694. [CrossRef]
92. Evans, R.M. Vimentin: The conundrum of the intermediate filament gene family. BioEssays 1998, 20, 79–86. [CrossRef]
93. Bornheim, R.; Müller, M.; Reuter, U.; Herrmann, H.; Büssow, H.; Magin, T.M. A dominant vimentin mutant upregulates Hsp70 and the activity of the ubiquitin-proteasome system, and causes posterior cataracts in transgenic mice. J. Cell Sci. 2008, 121, 3737–3746. [CrossRef] [PubMed]
94. Peuhu, E.; Virtakoivu, R.; Mai, A.; Wärri, A.; Ivaska, J. Epithelial vimentin plays a functional role in mammary gland development. Development 2017, 144, 4103–4113. [CrossRef] [PubMed]
95. Colucci-Guyon, E.; Giménez Y Ribotta, M.; Maurice, T.; Babinet, C.; Privat, A. Cerebellar defect and impaired motor coordination in mice lacking vimentin. Glia 1999, 25, 33–43. [CrossRef]
96. Geerts, A.; Eliasson, C.; Niki, T.; Wielant, A.; Vaeyens, F.; Pekny, M. Formation of normal desmin intermediate filaments in mouse hepatic stellate cells requires vimentin. Hepatology 2001, 33, 177–188. [CrossRef] [PubMed]
97. Nieminen, M.; Henttinen, T.; Merinen, M.; Marttila-Ichihara, F.; Eriksson, J.E.; Jalkanen, S. Vimentin function in lymphocyte adhesion and transcellular migration. Nat. Cell Biol. 2006, 8, 156–162. [CrossRef] [PubMed]
98. Langlois, B.; Belozertseva, E.; Parlakian, A.; Bourhim, M.; Gao-Li, J.; Blanc, J.; Tian, L.; Coletti, D.; Labat, C.; Ramdame-Cherif, Z.; et al. Vimentin knockout results in increased expression of sub-endothelial basement membrane components and carotid stiffness in mice. Sci. Rep. 2017, 7, 11628. [CrossRef] [PubMed]
99. Brown, M.J.; Hallam, J.A.; Colucci-Guyon, E.; Shaw, S. Rigidity of circulating lymphocytes is primarily conferred by vimentin intermediate filaments. J. Immunol. 2001, 166, 6640–6646. [CrossRef] [PubMed]
100. Schiffers, P.M.; Henrion, D.; Boulanger, C.M.; Colucci-Guyon, E.; Langa-Vuves, F.; van Essen, H.; Fazzi, G.E.; Lévy, B.I.; De Mey, J.G. Altered flow-induced arterial remodeling in vimentin-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2000, 20, 611–616. [CrossRef] [PubMed]
101. Antfolk, D.; Sjöqvist, M.; Cheng, F.; Isoniemi, K.; Duran, C.L.; Rivero-Muller, A.; Antila, C.; Niemi, R.; Landor, S.; Bouten, C.V.C.; et al. Selective regulation of Notch ligands during angiogenesis is mediated by vimentin. Proc. Natl. Acad. Sci. USA 2017, 114, E4574–E4581. [CrossRef] [PubMed]
102. Terzi, F.; Henrion, D.; Colucci-Guyon, E.; Federici, P.; Babinet, C.; Lévy, B.I.; Briand, P.; Friedlander, G. Reduction of renal mass is lethal in mice lacking vimentin. Role of endothelin-nitric oxide imbalance. J. Clin. Investig. 1997, 100, 1520–1528. [CrossRef] [PubMed]
103. Mor-Vaknin, N.; Legendre, M.; Yu, Y.; Serezani, C.H.C.; Garg, S.K.; Jatzek, A.; Swanson, M.D.; Gonzalez-Hernandez, M.J.; Teitz-Tennenbaum, S.; Punturieri, A.; et al. Murine colitis is mediated by vimentin. Sci. Rep. 2013, 3, 1045. [CrossRef] [PubMed]
104. Cheng, F.; Shen, Y.; Mohanasundaram, P.; Lindström, M.; Ivaska, J.; Ny, T.; Eriksson, J.E. Vimentin coordinates fibroblast proliferation and keratinocyte differentiation in wound healing via TGF-β-Slug signaling. Proc. Natl. Acad. Sci. USA 2016, 113, E4320–E4327. [CrossRef] [PubMed]
105. Eckes, B.; Colucci-Guyon, E.; Smola, H.; Nodder, S.; Babinet, C.; Krieg, T.; Martin, P. Impaired wound healing in embryonic and adult mice lacking vimentin. J. Cell Sci. 2000, 113 Pt 13, 2455–2462.
106. Huang, S.-H.; Chi, F.; Peng, L.; Bo, T.; Zhang, B.; Liu, L.-Q.; Wu, X.; Mor-Vaknin, N.; Markovitz, D.M.; Cao, H.; et al. Vimentin, a Novel NF-κB Regulator, Is Required for Meningitic Escherichia coli K1-Induced Pathogen Invasion and PMN Transmigration across the Blood-Brain Barrier. PLoS ONE 2016, 11, e0162641. [CrossRef] [PubMed]
107. Jiang, S.X.; Slinn, J.; Aylsworth, A.; Hou, S.T. Vimentin participates in microglia activation and neurotoxicity in cerebral ischemia. J. Neurochem. 2012, 122, 764–774. [CrossRef] [PubMed]
108. Moisan, É.; Chiasson, S.; Girard, D. The intriguing normal acute inflammatory response in mice lacking vimentin. Clin. Exp. Immunol. 2007, 150, 158–168. [CrossRef] [PubMed]
109. Park, D.; Xiang, A.P.; Mao, F.F.; Zhang, L.; Di, C.-G.; Liu, X.-M.; Shao, Y.; Ma, B.-F.; Lee, J.-H.; Ha, K.-S.; et al. Nestin is required for the proper self-renewal of neural stem cells. Stem Cells 2010, 28, 2162–2171. [CrossRef] [PubMed]
110. Goldman, R.D.; Cleland, M.M.; Murthy, S.N.P.; Mahammad, S.; Kuczmarski, E.R. Inroads into the structure and function of intermediate filament networks. J. Struct. Biol. 2012, 177, 14–23. [CrossRef] [PubMed]
111. Hollenbeck, P.J.; Bershadsky, A.D.; Pletjushkina, O.Y.; Tint, I.S.; Vasiliev, J.M. Intermediate filament collapse is an ATP-dependent and actin-dependent process. J. Cell Sci. 1989, 92 Pt 4, 621–631.
112. Huber, F.; Boire, A.; López, M.P.; Koenderink, G.H. Cytoskeletal crosstalk: When three different personalities team up. Curr. Opin. Cell Biol. 2015, 32, 39–47. [CrossRef] [PubMed]
113. Sakamoto, Y.; Boëda, B.; Etienne-Manneville, S. APC binds intermediate filaments and is required for their reorganization during cell migration. J. Cell Biol. 2013, 200, 249–258. [CrossRef] [PubMed]
114. Yoon, M.; Moir, R.D.; Prahlad, V.; Goldman, R.D. Motile properties of vimentin intermediate filament networks in living cells. J. Cell Biol. 1998, 143, 147–157. [CrossRef] [PubMed]
115. Ho, C.L.; Martys, J.L.; Mikhailov, A.; Gundersen, G.G.; Liem, R.K. Novel features of intermediate filament dynamics revealed by green fluorescent protein chimeras. J. Cell Sci. 1998, 111 Pt 13, 1767–1778.
116. Helfand, B.T.; Mikami, A.; Vallee, R.B.; Goldman, R.D. A requirement for cytoplasmic dynein and dynactin in intermediate filament network assembly and organization. J. Cell Biol. 2002, 157, 795–806. [CrossRef] [PubMed]
117. Martys, J.L.; Ho, C.L.; Liem, R.K.; Gundersen, G.G. Intermediate filaments in motion: Observations of intermediate filaments in cells using green fluorescent protein-vimentin. Mol. Biol. Cell 1999, 10, 1289–1295. [CrossRef] [PubMed]
118. Prahlad, V.; Helfand, B.T.; Langford, G.M.; Vale, R.D.; Goldman, R.D. Fast transport of neurofilament protein along microtubules in squid axoplasm. J. Cell Sci. 2000, 113 Pt 22, 3939–3946.
119. Gad, A.; Lach, S.; Crimaldi, L.; Gimona, M. Plectin deposition at podosome rings requires myosin contractility. Cell Motil. Cytoskelet. 2008, 65, 614–625. [CrossRef] [PubMed]
120. Esue, O.; Carson, A.A.; Tseng, Y.; Wirtz, D. A direct interaction between actin and vimentin filaments mediated by the tail domain of vimentin. J. Biol. Chem. 2006, 281, 30393–30399. [CrossRef] [PubMed]
121. Svitkina, T.M.; Verkhovsky, A.B.; Borisy, G.G. Plectin sidearms mediate interaction of intermediate filaments with microtubules and other components of the cytoskeleton. J. Cell Biol. 1996, 135, 991–1007. [CrossRef] [PubMed]
122. Jiu, Y.; Lehtimäki, J.; Tojkander, S.; Cheng, F.; Jäälinoja, H.; Liu, X.; Varjosalo, M.; Eriksson, J.E.; Lappalainen, P. Bidirectional Interplay between Vimentin Intermediate Filaments and Contractile Actin Stress Fibers. Cell Rep. 2015, 11, 1511–1518. [CrossRef] [PubMed]
123. Jiu, Y.; Peränen, J.; Schaible, N.; Cheng, F.; Eriksson, J.E.; Krishnan, R.; Lappalainen, P. Vimentin intermediate filaments control actin stress fiber assembly through GEF-H1 and RhoA. J. Cell Sci. 2017, 130, 892–902. [CrossRef] [PubMed]
124. Guo, M.; Ehrlicher, A.J.; Mahammad, S.; Fabich, H.; Jensen, M.H.; Moore, J.R.; Fredberg, J.J.; Goldman, R.D.; Weitz, D.A. The role of vimentin intermediate filaments in cortical and cytoplasmic mechanics. Biophys. J. 2013, 105, 1562–1568. [CrossRef] [PubMed]
125. Chang, L.; Barlan, K.; Chou, Y.-H.; Grin, B.; Lakonishok, M.; Serpinskaya, A.S.; Shumaker, D.K.; Herrmann, H.; Gelfand, V.I.; Goldman, R.D. The dynamic properties of intermediate filaments during organelle transport. J. Cell Sci. 2009, 122, 2914–2923. [CrossRef] [PubMed]
126. Tang, H.L.; Lung, H.L.; Wu, K.C.; Le, A.-H.P.; Tang, H.M.; Fung, M.C. Vimentin supports mitochondrial morphology and organization. Biochem. J. 2008, 410, 141–146. [CrossRef] [PubMed]
127. Nekrasova, O.E.; Mendez, M.G.; Chernoivanenko, I.S.; Tyurin-Kuzmin, P.A.; Kuczmarski, E.R.; Gelfand, V.I.; Goldman, R.D.; Minin, A.A. Vimentin intermediate filaments modulate the motility of mitochondria. Mol. Biol. Cell 2011, 22, 2282–2289. [CrossRef] [PubMed]
128. Tolstonog, G.V.; Belichenko-Weitzmann, I.V.; Lu, J.-P.; Hartig, R.; Shoeman, R.L.; Taub, U.; Traub, P. Spontaneously Immortalized Mouse Embryo Fibroblasts: Growth Behavior of Wild-Type and Vimentin-Deficient Cells in Relation to Mitochondrial Structure and Activity. DNA Cell Biol. 2005, 24, 680–709. [CrossRef] [PubMed]
129. Sarria, A.J.; Lieber, J.G.; Nordeen, S.K.; Evans, R.M. The presence or absence of a vimentin-type intermediate filament network affects the shape of the nucleus in human SW-13 cells. J. Cell Sci. 1994, 107 Pt 6, 1593–1607.
130. Gao, Y.; Sztul, E. A novel interaction of the Golgi complex with the vimentin intermediate filament cytoskeleton. J. Cell Biol. 2001, 152, 877–894. [CrossRef] [PubMed]
131. Johnston, J.A.; Ward, C.L.; Kopito, R.R. Aggresomes: A Cellular Response to Misfolded Proteins. J. Cell Biol. 1998, 143, 1883–1898. [CrossRef] [PubMed]
132. Ogrodnik, M.; Salmonowicz, H.; Brown, R.; Turkowska, J.; Średniawa, W.; Pattabiraman, S.; Amen, T.; Abraham, A.; Eichler, N.; Lyakhovetsky, R.; et al. Dynamic JUNQ inclusion bodies are asymmetrically inherited in mammalian cell lines through the asymmetric partitioning of vimentin. Proc. Natl. Acad. Sci. USA 2014, 111, 8049–8054. [CrossRef] [PubMed]
133. Janmey, P.A.; McCulloch, C.A. Cell mechanics: Integrating cell responses to mechanical stimuli. Annu. Rev. Biomed. Eng. 2007, 9, 1–34. [CrossRef] [PubMed]
134. Suresh, S. Biomechanics and biophysics of cancer cells. Acta Biomater. 2007, 3, 413–438. [CrossRef] [PubMed]
135. Fletcher, D.A.; Mullins, R.D. Cell mechanics and the cytoskeleton. Nature 2010, 463, 485–492. [CrossRef] [PubMed]
136. Sander, M.; Flesch, J.; Ott, A. Using cell monolayer rheology to probe average single cell mechanical properties. Biorheology 2015, 52, 269–278. [CrossRef] [PubMed]
137. Mendez, M.G.; Restle, D.; Janmey, P.A. Vimentin enhances cell elastic behavior and protects against compressive stress. Biophys. J. 2014, 107, 314–323. [CrossRef] [PubMed]
138. Chan, C.J.; Ekpenyong, A.E.; Golfier, S.; Li, W.; Chalut, K.J.; Otto, O.; Elgeti, J.; Guck, J.; Lautenschläger, F. Myosin II Activity Softens Cells in Suspension. Biophys. J. 2015, 108, 1856–1869. [CrossRef] [PubMed]
139. Fischer-Friedrich, E. Active Prestress Leads to an Apparent Stiffening of Cells through Geometrical Effects. Biophys. J. 2018, 114, 419–424. [CrossRef] [PubMed]
140. Eckes, B.; Dogic, D.; Colucci-Guyon, E.; Wang, N.; Maniotis, A.; Ingber, D.; Merckling, A.; Langa, F.; Aumailley, M.; Delouvée, A.; et al. Impaired mechanical stability, migration and contractile capacity in vimentin-deficient fibroblasts. J. Cell Sci. 1998, 111 Pt 13, 1897–1907.
141. Wang, N.; Stamenović, D. Contribution of intermediate filaments to cell stiffness, stiffening, and growth. Am. J. Physiol., Cell Physiol. 2000, 279, C188–C194. [CrossRef] [PubMed]
142. Helmke, B.P.; Goldman, R.D.; Davies, P.F. Rapid displacement of vimentin intermediate filaments in living endothelial cells exposed to flow. Circ. Res. 2000, 86, 745–752. [CrossRef] [PubMed]
143. Liu, C.-Y.; Lin, H.-H.; Tang, M.-J.; Wang, Y.-K. Vimentin contributes to epithelial-mesenchymal transition cancer cell mechanics by mediating cytoskeletal organization and focal adhesion maturation. Oncotarget 2015, 6, 15966–15983. [CrossRef] [PubMed]
144. Chen, C.; Yin, L.; Song, X.; Yang, H.; Ren, X.; Gong, X.; Wang, F.; Yang, L. Effects of vimentin disruption on the mechanoresponses of articular chondrocyte. Biochem. Biophys. Res. Commun. 2016, 469, 132–137. [CrossRef] [PubMed]
145. Keeling, M.C.; Flores, L.R.; Dodhy, A.H.; Murray, E.R.; Gavara, N. Actomyosin and vimentin cytoskeletal networks regulate nuclear shape, mechanics and chromatin organization. Sci. Rep. 2017, 7, 5219. [CrossRef] [PubMed]
146. van Loosdregt, I.A.E.W.; Weissenberger, G.; van Maris, M.P.F.H.L.; Oomens, C.W.J.; Loerakker, S.; Stassen, O.M.J.A.; Bouten, C.V.C. The Mechanical Contribution of Vimentin to Cellular Stress Generation. J. Biomech. Eng. 2018, 140, 061006. [CrossRef] [PubMed]
147. Sharma, P.; Bolten, Z.T.; Wagner, D.R.; Hsieh, A.H. Deformability of Human Mesenchymal Stem Cells Is Dependent on Vimentin Intermediate Filaments. Ann. Biomed. Eng. 2017, 45, 1365–1374. [CrossRef] [PubMed]
148. Haudenschild, D.R.; Chen, J.; Pang, N.; Steklov, N.; Grogan, S.P.; Lotz, M.K.; D’Lima, D.D. Vimentin contributes to changes in chondrocyte stiffness in osteoarthritis. J. Orthop. Res. 2011, 29, 20–25. [CrossRef] [PubMed]
149. Gladilin, E.; Gonzalez, P.; Eils, R. Dissecting the contribution of actin and vimentin intermediate filaments to mechanical phenotype of suspended cells using high-throughput deformability measurements and computational modeling. J. Biomech. 2014, 47, 2598–2605. [CrossRef] [PubMed]
150. Charrier, E.E.; Janmey, P.A. Mechanical Properties of Intermediate Filament Proteins. In Intermediate Filament Proteins; Elsevier: New York, NY, USA, 2016; pp. 35–57.
151. Fallqvist, B.; Fielden, M.L.; Pettersson, T.; Nordgren, N.; Kroon, M.; Gad, A.K.B. Experimental and computational assessment of F-actin influence in regulating cellular stiffness and relaxation behaviour of fibroblasts. J. Mech. Behav. Biomed. Mater. 2016, 59, 168–184. [CrossRef] [PubMed]
152. Terriac, E.; Coceano, G.; Mavajian, Z.; Hageman, T.A.G.; Christ, A.F.; Testa, I.; Lautenschläger, F.; Gad, A.K.B. Vimentin Levels and Serine 71 Phosphorylation in the Control of Cell-Matrix Adhesions, Migration Speed, and Shape of Transformed Human Fibroblasts. Cells 2017, 6, 2. [CrossRef] [PubMed]
153. Kreis, S.; Schonfeld, H.; Melchior, C.; Steiner, B.; Kieffer, N. The intermediate filament protein vimentin binds specifically to a recombinant integrinalpha2/beta1 cytoplasmic tail complex and co-localizes with nativealpha2/beta1 in endothelial cell focal adhesions. Exp. Cell Res. 2005, 305, 110–121. [CrossRef] [PubMed]
154. Bhattacharya, R.; Gonzalez, A.M.; DeBiase, P.J.; Trejo, H.E.; Goldman, R.D.; Flitney, F.W.; Jones, J.C.R. Recruitment of vimentin to the cell surface by 3 integrin and plectin mediates adhesion strength. J. Cell Sci. 2009, 122, 1390–1400. [CrossRef] [PubMed]
155. Colburn, Z.T.; Jones, J.C.R. Complexes of α6β4 integrin and vimentin signal to regulate epithelial cell migration. J. Cell Sci. 2018. [CrossRef] [PubMed]
156. Foisner, R.; Leichtfried, F.E.; Herrmann, H.; Small, J.V.; Lawson, D.; Wiche, G. Cytoskeleton-associated plectin: In situ localization, in vitro reconstitution, and binding to immobilized intermediate filament proteins. J. Cell Biol. 1988, 106, 723–733. [CrossRef] [PubMed]
157. Burgstaller, G.; Gregor, M.; Winter, L.; Wiche, G. Keeping the Vimentin Network under Control: Cell–Matrix Adhesion–associated Plectin 1f Affects Cell Shape and Polarity of Fibroblasts. Mol. Biol. Cell 2010, 21, 3362–3375. [CrossRef] [PubMed]
158. Kim, H.; Nakamura, F.; Lee, W.; Shifrin, Y.; Arora, P.; McCulloch, C.A. Filamin A is required for vimentin-mediated cell adhesion and spreading. Am. J. Physiol. Cell Physiol. 2010, 298, C221–C236. [CrossRef] [PubMed]
159. Kim, H.; Nakamura, F.; Lee, W.; Hong, C.; Pérez-Sala, D.; McCulloch, C.A. Regulation of cell adhesion to collagen via β1 integrins is dependent on interactions of filamin A with vimentin and protein kinase C epsilon. Exp. Cell Res. 2010, 316, 1829–1844. [CrossRef] [PubMed]
160. Correia, I.; Chu, D.; Chou, Y.H.; Goldman, R.D.; Matsudaira, P. Integrating the actin and vimentin cytoskeletons. adhesion-dependent formation of fimbrin-vimentin complexes in macrophages. J. Cell Biol. 1999, 146, 831–842. [CrossRef] [PubMed]
161. Kim, J.; Yang, C.; Kim, E.J.; Jang, J.; Kim, S.-J.; Kang, S.M.; Kim, M.G.; Jung, H.; Park, D.; Kim, C. Vimentin filaments regulate integrin-ligand interactions by binding to the cytoplasmic tail of integrin β3. J. Cell Sci. 2016, 129, 2030–2042. [CrossRef] [PubMed]
162. Kim, J.; Jang, J.; Yang, C.; Kim, E.J.; Jung, H.; Kim, C. Vimentin filament controls integrin α5β1-mediated cell adhesion by binding to integrin through its Ser38 residue. FEBS Lett. 2016, 590, 3517–3525. [CrossRef] [PubMed]
163. Tsuruta, D.; Jones, J.C.R. The vimentin cytoskeleton regulates focal contact size and adhesion of endothelial cells subjected to shear stress. J. Cell Sci. 2003, 116, 4977–4984. [CrossRef] [PubMed]
164. Gregor, M.; Osmanagic-Myers, S.; Burgstaller, G.; Wolfram, M.; Fischer, I.; Walko, G.; Resch, G.P.; Jörgl, A.; Herrmann, H.; Wiche, G. Mechanosensing through focal adhesion-anchored intermediate filaments. FASEB J. 2014, 28, 715–729. [CrossRef] [PubMed]
165. Mendez, M.G.; Kojima, S.-I.; Goldman, R.D. Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition. FASEB J. 2010, 24, 1838–1851. [CrossRef] [PubMed]
166. Helfand, B.T.; Mendez, M.G.; Murthy, S.N.P.; Shumaker, D.K.; Grin, B.; Mahammad, S.; Aebi, U.; Wedig, T.; Wu, Y.I.; Hahn, K.M.; et al. Vimentin organization modulates the formation of lamellipodia. Mol. Biol. Cell 2011, 22, 1274–1289. [CrossRef] [PubMed]
167. Rönnlund, D.; Gad, A.K.B.; Blom, H.; Aspenström, P.; Widengren, J. Spatial organization of proteins in metastasizing cells. Cytometry Part A 2013, 83, 855–865. [CrossRef] [PubMed]
168. Hagenfeld, D.; Borkenhagen, B.; Schulz, T.; Schillers, H.; Schumacher, U.; Prehm, P. Hyaluronan Export through Plasma Membranes Depends on Concurrent K+ Efflux by Kir Channels. PLoS ONE 2012, 7, e39096. [CrossRef] [PubMed]
169. Aruffo, A.; Stamenkovic, I.; Melnick, M.; Underhill, C.B.; Seed, B. CD44 is the principal cell surface receptor for hyaluronate. Cell 1990, 61, 1303–1313. [CrossRef]
170. Hall, C.L.; Wang, C.; Lange, L.A.; Turley, E.A. Hyaluronan and the hyaluronan receptor RHAMM promote focal adhesion turnover and transient tyrosine kinase activity. J. Cell Biol. 1994, 126, 575–588. [CrossRef] [PubMed]
171. Savani, R.C.; Cao, G.; Pooler, P.M.; Zaman, A.; Zhou, Z.; DeLisser, H.M. Differential Involvement of the Hyaluronan (HA) Receptors CD44 and Receptor for HA-mediated Motility in Endothelial Cell Function and Angiogenesis. J. Biol. Chem. 2001, 276, 36770–36778. [CrossRef] [PubMed]
172. Kim, Y.; Kumar, S. CD44-Mediated Adhesion to Hyaluronic Acid Contributes to Mechanosensing and Invasive Motility. Mol. Cancer Res. MCR 2014, 12, 1416–1429. [CrossRef] [PubMed]
173. Päll, T.; Pink, A.; Kasak, L.; Turkina, M.; Anderson, W.; Valkna, A.; Kogerman, P. Soluble CD44 Interacts with Intermediate Filament Protein Vimentin on Endothelial Cell Surface. PLoS ONE 2011, 6, e29305. [CrossRef] [PubMed]
174. Zoltan-Jones, A.; Huang, L.; Ghatak, S.; Toole, B.P. Elevated Hyaluronan Production Induces Mesenchymal and Transformed Properties in Epithelial Cells. J. Biol. Chem. 2003, 278, 45801–45810. [CrossRef] [PubMed]
175. Mor-Vaknin, N.; Punturieri, A.; Sitwala, K.; Markovitz, D.M. Vimentin is secreted by activated macrophages. Nat. Cell Biol. 2003, 5, 59–63. [CrossRef] [PubMed]
176. Xu, B.; deWaal, R.M.; Mor-Vaknin, N.; Hibbard, C.; Markovitz, D.M.; Kahn, M.L. The endothelial cell-specific antibody PAL-E identifies a secreted form of vimentin in the blood vasculature. Mol. Cell. Biol. 2004, 24, 9198–9206. [CrossRef] [PubMed]
177. Greco, T.M.; Seeholzer, S.H.; Mak, A.; Spruce, L.; Ischiropoulos, H. Quantitative Mass Spectrometry-based Proteomics Reveals the Dynamic Range of Primary Mouse Astrocyte Protein Secretion. J. Proteome Res. 2010, 9, 2764–2774. [CrossRef] [PubMed]
178. Cordero-Llana, O.; Scott, S.A.; Maslen, S.L.; Anderson, J.M.; Boyle, J.; Chowhdury, R.-R.; Tyers, P.; Barker, R.A.; Kelly, C.M.; Rosser, A.E.; et al. Clusterin secreted by astrocytes enhances neuronal differentiation from human neural precursor cells. Cell Death Differ. 2011, 18, 907–913. [CrossRef] [PubMed]
179. Shigyo, M.; Kuboyama, T.; Sawai, Y.; Tada-Umezaki, M.; Tohda, C. Extracellular vimentin interacts with insulin-like growth factor 1 receptor to promote axonal growth. Sci. Rep. 2015, 5, 4977. [CrossRef] [PubMed]
180. Teshigawara, K.; Kuboyama, T.; Shigyo, M.; Nagata, A.; Sugimoto, K.; Matsuya, Y.; Tohda, C. A novel compound, denosomin, ameliorates spinal cord injury via axonal growth associated with astrocyte-secreted vimentin. Br. J. Pharmacol. 2013, 168, 903–919. [CrossRef] [PubMed]
181. Shigyo, M.; Tohda, C. Extracellular vimentin is a novel axonal growth facilitator for functional recovery in spinal cord-injured mice. Sci. Rep. 2016, 6, 931. [CrossRef] [PubMed]
182. Jørgensen, M.L.; Møller, C.K.; Rasmussen, L.; Boisen, L.; Pedersen, H.; Kristensen, P. An anti vimentin antibody promotes tube formation. Sci. Rep. 2017, 7, 3576. [CrossRef] [PubMed]
183. Thiagarajan, P.S.; Yakubenko, V.P.; Elsori, D.H.; Yadav, S.P.; Willard, B.; Tan, C.D.; Rodriguez, E.R.; Febbraio, M.; Cathcart, M.K. Vimentin is an endogenous ligand for the pattern recognition receptor Dectin-1. Cardiovasc. Res. 2013, 99, 494–504. [CrossRef] [PubMed]
184. Da, Q.; Behymer, M.; Correa, J.I.; Vijayan, K.V.; Cruz, M.A. Platelet adhesion involves a novel interaction between vimentin and von Willebrand factor under high shear stress. Blood 2014, 123, 2715–2721. [CrossRef] [PubMed]
185. Lam, F.W.; Da, Q.; Guillory, B.; Cruz, M.A. Recombinant Human Vimentin Binds to P-Selectin and Blocks Neutrophil Capture and Rolling on Platelets and Endothelium. J. Immunol. 2018. [CrossRef] [PubMed]
186. Vossenaar, E.R.; Després, N.; Lapointe, E.; van der Heijden, A.; Lora, M.; Senshu, T.; van Venrooij, W.J.; Ménard, H.A. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res. Ther. 2004, 6, R142–R150. [CrossRef] [PubMed]
187. Poulsom, H.; Charles, P.J. Antibodies to citrullinated vimentin are a specific and sensitive marker for the diagnosis of rheumatoid arthritis. Clin. Rev. Allergy Immunol. 2008, 34, 4–10. [CrossRef] [PubMed]
188. Demoruelle, M.K.; Deane, K. Antibodies to citrullinated protein antigens (ACPAs): Clinical and pathophysiologic significance. Curr. Rheumatol. Rep. 2011, 13, 421–430. [CrossRef] [PubMed]
189. Schäfer, G.; Graham, L.M.; Lang, D.M.; Blumenthal, M.J.; Bergant Marušič, M.; Katz, A.A. Vimentin Modulates Infectious Internalization of Human Papillomavirus 16 Pseudovirions. J. Virol. 2017, 91, e00307-17. [CrossRef] [PubMed]
190. Ghosh, P.; Halvorsen, E.M.; Ammendolia, D.A.; Mor-Vaknin, N.; O’Riordan, M.X.D.; Brumell, J.H.; Markovitz, D.M.; Higgins, D.E. Invasion of the Brain by Listeria monocytogenes Is Mediated by InlF and Host Cell Vimentin. mBio 2018, 9, e00160-18. [CrossRef] [PubMed]
191. Bastounis, E.E.; Yeh, Y.-T.; Theriot, J.A. Matrix stiffness modulates infection of endothelial cells by Listeria monocytogenes via expression of cell surface vimentin. Mol. Biol. Cell 2018, 29, 1571–1589. [CrossRef] [PubMed]
192. Yang, J.; Zou, L.; Yang, Y.; Yuan, J.; Hu, Z.; Liu, H.; Peng, H.; Shang, W.; Zhang, X.; Zhu, J.; et al. Superficial vimentin mediates DENV-2 infection of vascular endothelial cells. Sci. Rep. 2016, 6, 69. [CrossRef] [PubMed]
193. Sharma, M.; Liu, W.; Perincheri, S.; Gunasekaran, M.; Mohanakumar, T. Exosomes expressing the self-antigens myosin and vimentin play an important role in syngeneic cardiac transplant rejection induced by antibodies to cardiac myosin. Am. J. Transplant. 2018, 18, 1626–1635. [CrossRef] [PubMed]
194. Press, J.Z.; Reyes, M.; Pitteri, S.J.; Pennil, C.; Garcia, R.; Goff, B.A.; Hanash, S.M.; Swisher, E.M. Microparticles from ovarian carcinomas are shed into ascites and promote cell migration. Int. J. Gynecol. Cancer 2012, 22, 546–552. [CrossRef] [PubMed]
195. Paul, C.D.; Mistriotis, P.; Konstantopoulos, K. Cancer cell motility: Lessons from migration in confined spaces. Nat. Rev. Cancer 2016, 17, 131–140. [CrossRef] [PubMed]
196. Reig, G.; Pulgar, E.; Concha, M.L. Cell migration: From tissue culture to embryos. Development 2014, 141, 1999–2013. [CrossRef] [PubMed]
197. De Pascalis, C.; Etienne-Manneville, S. Single and collective cell migration: The mechanics of adhesions. Mol. Biol. Cell 2017, 28, 1833–1846. [CrossRef] [PubMed]
198. Mayor, R.; Etienne-Manneville, S. The front and rear of collective cell migration. Nat. Rev. Mol. Cell Biol. 2016, 17, 97–109. [CrossRef] [PubMed]
199. Petrie, R.J.; Koo, H.; Yamada, K.M. Generation of compartmentalized pressure by a nuclear piston governs cell motility in a 3D matrix. Science 2014, 345, 1062–1065. [CrossRef] [PubMed]
200. Blanchoin, L.; Boujemaa-Paterski, R.; Sykes, C.; Plastino, J. Actin Dynamics, Architecture, and Mechanics in Cell Motility. Physiol. Rev. 2014, 94, 235–263. [CrossRef] [PubMed]
201. Rogel, M.R.; Soni, P.N.; Troken, J.R.; Sitikov, A.; Trejo, H.E.; Ridge, K.M. Vimentin is sufficient and required for wound repair and remodeling in alveolar epithelial cells. FASEB J. 2011, 25, 3873–3883. [CrossRef] [PubMed]
202. Cheng, F.; Eriksson, J.E. Intermediate Filaments and the Regulation of Cell Motility during Regeneration and Wound Healing. Cold Spring Harb. Perspect. Biol. 2017, 9, a022046. [CrossRef] [PubMed]
203. Hay, E.D. An Overview of Epithelio-Mesenchymal Transformation. Cells Tissues Organs 1995, 154, 8–20. [CrossRef]
204. Kalluri, R.; Neilson, E.G. Epithelial-mesenchymal transition and its implications for fibrosis. J. Clin. Investig. 2003, 112, 1776–1784. [CrossRef] [PubMed]
205. Kalluri, R.; Weinberg, R.A. The basics of epithelial-mesenchymal transition. J. Clin. Investig. 2009, 119, 1420–1428. [CrossRef] [PubMed]
206. Ivaska, J. Vimentin: Central hub in EMT induction? Small GTPases 2011, 2, 51–53. [CrossRef] [PubMed]
207. Gilles, C.; Polette, M.; Zahm, J.M.; Tournier, J.M.; Volders, L.; Foidart, J.M.; Birembaut, P. Vimentin contributes to human mammary epithelial cell migration. J. Cell Sci. 1999, 112 Pt 24, 4615–4625.
208. Liao, G.; Gundersen, G.G. Kinesin is a candidate for cross-bridging microtubules and intermediate filaments. Selective binding of kinesin to detyrosinated tubulin and vimentin. J. Biol. Chem. 1998, 273, 9797–9803. [CrossRef] [PubMed]
209. Perlson, E.; Hanz, S.; Ben-Yaakov, K.; Segal-Ruder, Y.; Seger, R.; Fainzilber, M. Vimentin-dependent spatial translocation of an activated MAP kinase in injured nerve. Neuron 2005, 45, 715–726. [CrossRef] [PubMed]
210. Gyoeva, F.K.; Gelfand, V.I. Coalignment of vimentin intermediate filaments with microtubules depends on kinesin. Nature 1991, 353, 445–448. [CrossRef] [PubMed]
211. Tzivion, G.; Luo, Z.-J.; Avruch, J. Calyculin A-induced Vimentin Phosphorylation Sequesters 14-3-3 and Displaces Other 14-3-3 Partners in Vivo. J. Biol. Chem. 2000, 275, 29772–29778. [CrossRef] [PubMed]
212. Gómez-Suárez, M.; Gutiérrez-Martínez, I.Z.; Hernández-Trejo, J.A.; Hernández-Ruiz, M.; Suárez-Pérez, D.; Candelario, A.; Kamekura, R.; Medina-Contreras, O.; Schnoor, M.; Ortiz-Navarrete, V.; et al. 14-3-3 Proteins regulate Akt Thr308 phosphorylation in intestinal epithelial cells. Cell Death Differ. 2016, 23, 1060–1072. [CrossRef] [PubMed]
213. Fortier, A.-M.; Van Themsche, C.; Asselin, E.; Cadrin, M. Akt isoforms regulate intermediate filament protein levels in epithelial carcinoma cells. FEBS Lett. 2010, 584, 984–988. [CrossRef] [PubMed]
214. Buccione, R.; Orth, J.D.; McNiven, M.A. Foot and mouth: Podosomes, invadopodia and circular dorsal ruffles. Nat. Rev. Mol. Cell Biol. 2004, 5, 647–657. [CrossRef] [PubMed]
215. Lorenz, M.; Yamaguchi, H.; Wang, Y.; Singer, R.H.; Condeelis, J. Imaging Sites of N-WASP Activity in Lamellipodia and Invadopodia of Carcinoma Cells. Curr. Biol. 2004, 14, 697–703. [CrossRef] [PubMed]
216. Yamaguchi, H.; Lorenz, M.; Kempiak, S.; Sarmiento, C.; Coniglio, S.; Symons, M.; Segall, J.; Eddy, R.; Miki, H.; Takenawa, T.; et al. Molecular mechanisms of invadopodium formation. J. Cell Biol. 2005, 168, 441–452. [CrossRef] [PubMed]
217. Baldassarre, M.; Ayala, I.; Beznoussenko, G.; Giacchetti, G.; Machesky, L.M.; Luini, A.; Buccione, R. Actin dynamics at sites of extracellular matrix degradation. Eur. J. Cell Biol. 2006, 85, 1217–1231. [CrossRef] [PubMed]
218. Bowden, E.; Onikoyi, E.; Slack, R.; Myoui, A.; Yoneda, T.; Yamada, K.; Mueller, S. Co-localization of cortactin and phosphotyrosine identifies active invadopodia in human breast cancer cells. Exp. Cell Res. 2006, 312, 1240–1253. [CrossRef] [PubMed]
219. Weaver, A.M. Invadopodia: Specialized Cell Structures for Cancer Invasion. Clin. Exp. Metastasis 2006, 23, 97–105. [CrossRef] [PubMed]
220. Clark, E.S.; Whigham, A.S.; Yarbrough, W.G.; Weaver, A.M. Cortactin is an essential regulator of matrix metalloproteinase secretion and extracellular matrix degradation in invadopodia. Cancer Res. 2007, 67, 4227–4235. [CrossRef] [PubMed]
221. Philippar, U.; Roussos, E.T.; Oser, M.; Yamaguchi, H.; Kim, H.-D.; Giampieri, S.; Wang, Y.; Goswami, S.; Wyckoff, J.B.; Lauffenburger, D.A.; et al. A Mena Invasion Isoform Potentiates EGF-Induced Carcinoma Cell Invasion and Metastasis. Dev. Cell 2008, 15, 813–828. [CrossRef] [PubMed]
222. Svitkina, T.M.; Borisy, G.G. Arp2/3 complex and actin depolymerizing factor/cofilin in dendritic organization and treadmilling of actin filament array in lamellipodia. J. Cell Biol. 1999, 145, 1009–1026. [CrossRef] [PubMed]
223. Lizárraga, F.; Poincloux, R.; Romao, M.; Montagnac, G.; Le Dez, G.; Bonne, I.; Rigaill, G.; Raposo, G.; Chavrier, P. Diaphanous-related formins are required for invadopodia formation and invasion of breast tumor cells. Cancer Res. 2009, 69, 2792–2800. [CrossRef] [PubMed]
224. Mattila, P.K.; Lappalainen, P. Filopodia: molecular architecture and cellular functions. Nat. Rev. Mol. Cell Biol. 2008, 9, 446–454. [CrossRef] [PubMed]
225. Gupton, S.L.; Gertler, F.B. Filopodia: The fingers that do the walking. Sci. STKE 2007, 2007, re5. [CrossRef] [PubMed]
226. Schoumacher, M.; Goldman, R.D.; Louvard, D.; Vignjevic, D.M. Actin, microtubules, and vimentin intermediate filaments cooperate for elongation of invadopodia. J. Cell Biol. 2010, 189, 541–556. [CrossRef] [PubMed]
227. Sutoh Yoneyama, M.; Hatakeyama, S.; Habuchi, T.; Inoue, T.; Nakamura, T.; Funyu, T.; Wiche, G.; Ohyama, C.; Tsuboi, S. Vimentin intermediate filament and plectin provide a scaffold for invadopodia, facilitating cancer cell invasion and extravasation for metastasis. Eur. J. Cell Biol. 2014, 93, 157–169. [CrossRef] [PubMed]
228. Lund, N.; Henrion, D.; Tiede, P.; Ziche, M.; Schunkert, H.; Ito, W.D. Vimentin expression influences flow dependent VASP phosphorylation and regulates cell migration and proliferation. Biochem. Biophys. Res. Commun. 2010, 395, 401–406. [CrossRef] [PubMed]
229. Havel, L.S.; Kline, E.R.; Salgueiro, A.M.; Marcus, A.I. Vimentin regulates lung cancer cell adhesion through a VAV2-Rac1 pathway to control focal adhesion kinase activity. Oncogene 2015, 34, 1979–1990. [CrossRef] [PubMed]
230. Whipple, R.A.; Cheung, A.M.; Martin, S.S. Detyrosinated microtubule protrusions in suspended mammary epithelial cells promote reattachment. Exp. Cell Res. 2007, 313, 1326–1336. [CrossRef] [PubMed]
231. Whipple, R.A.; Balzer, E.M.; Cho, E.H.; Matrone, M.A.; Yoon, J.R.; Martin, S.S. Vimentin filaments support extension of tubulin-based microtentacles in detached breast tumor cells. Cancer Res. 2008, 68, 5678–5688. [CrossRef] [PubMed]
232. Killilea, A.N.; Csencsits, R.; Le, E.B.N.T.; Patel, A.M.; Kenny, S.J.; Xu, K.; Downing, K.H. Cytoskeletal organization in microtentacles. Exp. Cell Res. 2017, 357, 291–298. [CrossRef] [PubMed]
233. Brown, M.S.; Goldstein, J.L. A receptor-mediated pathway for cholesterol homeostasis. Science 1986, 232, 34–47. [CrossRef] [PubMed]
234. Sarria, A.J.; Panini, S.R.; Evans, R.M. A functional role for vimentin intermediate filaments in the metabolism of lipoprotein-derived cholesterol in human SW-13 cells. J. Biol. Chem. 1992, 267, 19455–19463. [PubMed]
235. Almahbobi, G.; Hall, P.F. The role of intermediate filaments in adrenal steroidogenesis. J. Cell Sci. 1990, 97 Pt 4, 679–687.
236. Rittling, S.R.; Baserga, R. Functional analysis and growth factor regulation of the human vimentin promoter. Mol. Cell. Biol. 1987, 7, 3908–3915. [CrossRef] [PubMed]
237. Byun, Y.; Chen, F.; Chang, R.; Trivedi, M.; Green, K.J.; Cryns, V.L. Caspase cleavage of vimentin disrupts intermediate filaments and promotes apoptosis. Cell Death Differ. 2001, 8, 443–450. [CrossRef] [PubMed]
238. Olson, E.N.; Capetanaki, Y.G. Developmental regulation of intermediate filament and actin mRNAs during myogenesis is disrupted by oncogenic ras genes. Oncogene 1989, 4, 907–913. [PubMed]
239. Capetanaki, Y.; Smith, S.; Heath, J.P. Overexpression of the vimentin gene in transgenic mice inhibits normal lens cell differentiation. J. Cell Biol. 1989, 109, 1653–1664. [CrossRef] [PubMed]
240. Mou, L.; Xu, J.-Y.; Li, W.; Lei, X.; Wu, Y.; Xu, G.; Kong, X.; Xu, G.-T. Identification of vimentin as a novel target of HSF4 in lens development and cataract by proteomic analysis. Investig. Ophthalmol. Vis. Sci. 2010, 51, 396–404. [CrossRef] [PubMed]
241. Hol, E.M.; Capetanaki, Y. Type III Intermediate Filaments Desmin, Glial Fibrillary Acidic Protein (GFAP), Vimentin, and Peripherin. Cold Spring Harb. Perspect. Biol. 2017, 9, a021642. [CrossRef] [PubMed]
242. Chen, M.; Puschmann, T.B.; Marasek, P.; Inagaki, M.; Pekna, M.; Wilhelmsson, U.; Pekny, M. Increased Neuronal Differentiation of Neural Progenitor Cells Derived from Phosphovimentin-Deficient Mice. Mol. Neurobiol. 2018, 55, 5478–5489. [CrossRef] [PubMed]
243. Vuoriluoto, K.; Haugen, H.; Kiviluoto, S.; Mpindi, J.-P.; Nevo, J.; Gjerdrum, C.; Tiron, C.; Lorens, J.B.; Ivaska, J. Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer. Oncogene 2011, 30, 1436–1448. [CrossRef] [PubMed]
244. Lian, N.; Wang, W.; Li, L.; Elefteriou, F.; Yang, X. Vimentin Inhibits ATF4-mediated OsteocalcinTranscription and Osteoblast Differentiation. J. Biol. Chem. 2009, 284, 30518–30525. [CrossRef] [PubMed]
245. Ferreira, L.R.; Moussatché, N.; Moura Neto, V. Rearrangement of intermediate filament network of BHK-21 cells infected with vaccinia virus. Arch. Virol. 1994, 138, 273–285. [CrossRef] [PubMed]
246. Leader, M.; Collins, M.; Patel, J.; Henry, K. Vimentin: An evaluation of its role as a tumour marker. Histopathology 2007, 11, 63–72. [CrossRef]
247. Virtakoivu, R.; Mai, A.; Mattila, E.; De Franceschi, N.; Imanishi, S.Y.; Corthals, G.; Kaukonen, R.; Saari, M.; Cheng, F.; Torvaldson, E.; et al. Vimentin-ERK Signaling Uncouples Slug Gene Regulatory Function. Cancer Res. 2015, 75, 2349–2362. [CrossRef] [PubMed]
248. Upton, M.P.; Hirohashi, S.; Tome, Y.; Miyazawa, N.; Suemasu, K.; Shimosato, Y. Expression of vimentin in surgically resected adenocarcinomas and large cell carcinomas of lung. Am. J. Surg. Pathol. 1986, 10, 560–567. [CrossRef] [PubMed]
249. Dauphin, M.; Barbe, C.; Lemaire, S.; Nawrocki-Raby, B.; Lagonotte, E.; Delepine, G.; Birembaut, P.; Gilles, C.; Polette, M. Vimentin expression predicts the occurrence of metastases in non small cell lung carcinomas. Lung Cancer 2013, 81, 117–122. [CrossRef] [PubMed]
250. Al-Saad, S.; Al-Shibli, K.; Donnem, T.; Persson, M.; Bremnes, R.M.; Busund, L.-T. The prognostic impact of NF-kappaB p105, vimentin, E-cadherin and Par6 expression in epithelial and stromal compartment in non-small-cell lung cancer. Br. J. Cancer 2008, 99, 1476–1483. [CrossRef] [PubMed]
251. Richardson, F.; Young, G.D.; Sennello, R.; Wolf, J.; Argast, G.M.; Mercado, P.; Davies, A.; Epstein, D.M.; Wacker, B. The evaluation of E-Cadherin and vimentin as biomarkers of clinical outcomes among patients with non-small cell lung cancer treated with erlotinib as second-or third-line therapy. Anticancer Res. 2012, 32, 537–552. [PubMed]
252. Rho, J.-H.; Roehrl, M.H.A.; Wang, J.Y. Glycoproteomic Analysis of Human Lung Adenocarcinomas Using Glycoarrays and Tandem Mass Spectrometry: Differential Expression and Glycosylation Patterns of Vimentin and Fetuin A Isoforms. Protein J. 2009, 28, 148–160. [CrossRef] [PubMed]
253. Richardson, A.M.; Havel, L.S.; Koyen, A.E.; Konen, J.M.; Shupe, J.; Wiles, W.G.; Martin, W.D.; Grossniklaus, H.E.; Sica, G.; Gilbert-Ross, M.; et al. Vimentin Is Required for Lung Adenocarcinoma Metastasis via Heterotypic Tumor Cell-Cancer-Associated Fibroblast Interactions during Collective Invasion. Clin. Cancer Res. 2018, 24, 420–432. [CrossRef] [PubMed]
254. Alkasalias, T.; Alexeyenko, A.; Hennig, K.; Danielsson, F.; Lebbink, R.J.; Fielden, M.; Turunen, S.P.; Lehti, K.; Kashuba, V.; Madapura, H.S.; et al. RhoA knockout fibroblasts lose tumor-inhibitory capacity in vitro and promote tumor growth in vivo. Proc. Natl. Acad. Sci. USA 2017, 114, E1413–E1421. [CrossRef] [PubMed]
255. Gilles, C.; Polette, M.; Mestdagt, M.; Nawrocki-Raby, B.; Ruggeri, P.; Birembaut, P.; Foidart, J.-M. Transactivation of vimentin by beta-catenin in human breast cancer cells. Cancer Res. 2003, 63, 2658–2664. [PubMed]
256. Kokkinos, M.I.; Wafai, R.; Wong, M.K.; Newgreen, D.F.; Thompson, E.W.; Waltham, M. Vimentin and epithelial-mesenchymal transition in human breast cancer–observations in vitro and in vivo. Cells Tissues Organs 2007, 185, 191–203. [CrossRef] [PubMed]
257. Korsching, E.; Packeisen, J.; Liedtke, C.; Hungermann, D.; Wülfing, P.; van Diest, P.J.; Brandt, B.; Boecker, W.; Buerger, H. The origin of vimentin expression in invasive breast cancer: Epithelial-mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential? J. Pathol. 2005, 206, 451–457. [CrossRef] [PubMed]
258. Mikesh, L.M.; Kumar, M.; Erdag, G.; Hogan, K.T.; Molhoek, K.R.; Mayo, M.W.; Slingluff, C.L. Evaluation of molecular markers of mesenchymal phenotype in melanoma. Melanoma Res. 2010, 20, 485–495. [CrossRef] [PubMed]
259. Chu, Y.W.; Seftor, E.A.; Romer, L.H.; Hendrix, M.J. Experimental coexpression of vimentin and keratin intermediate filaments in human melanoma cells augments motility. Am. J. Pathol. 1996, 148, 63–69. [PubMed]
260. Hendrix, M.J.; Seftor, E.A.; Chu, Y.W.; Seftor, R.E.; Nagle, R.B.; McDaniel, K.M.; Leong, S.P.; Yohem, K.H.; Leibovitz, A.M.; Meyskens, F.L. Coexpression of vimentin and keratins by human melanoma tumor cells: Correlation with invasive and metastatic potential. J. Natl. Cancer Inst. 1992, 84, 165–174. [CrossRef] [PubMed]
261. Li, M.; Zhang, B.; Sun, B.; Wang, X.; Ban, X.; Sun, T.; Liu, Z.; Zhao, X. A novel function for vimentin: The potential biomarker for predicting melanoma hematogenous metastasis. J. Exp. Clin. Cancer Res. CR 2010, 29, 109. [CrossRef] [PubMed]
262. Webber, M. Acinar differentiation by non-malignant immortalized human prostatic epithelial cells and its loss by malignant cells. Carcinogenesis 1997, 18, 1225–1231. [CrossRef] [PubMed]
263. Bello-DeOcampo, D.; Kleinman, H.K.; Webber, M.M. The role of α6β1 integrin and EGF in normal and malignant acinar morphogenesis of human prostatic epithelial cells. Mutat. Res./Fundam. Mol. Mech. Mutagen. 2001, 480–481, 209–217. [CrossRef]
264. Zhang, X.; Fournier, M.V.; Ware, J.L.; Bissell, M.J.; Yacoub, A.; Zehner, Z.E. Inhibition of vimentin or beta1 integrin reverts morphology of prostate tumor cells grown in laminin-rich extracellular matrix gels and reduces tumor growth in vivo. Mol. Cancer Ther. 2009, 8, 499–508. [CrossRef] [PubMed]
265. Ivaska, J.; Vuoriluoto, K.; Huovinen, T.; Izawa, I.; Inagaki, M.; Parker, P.J. PKCepsilon-mediated phosphorylation of vimentin controls integrin recycling and motility. EMBO J. 2005, 24, 3834–3845. [CrossRef] [PubMed]
266. Hafeez, B.B.; Zhong, W.; Weichert, J.; Dreckschmidt, N.E.; Jamal, M.S.; Verma, A.K. Genetic ablation of PKC epsilon inhibits prostate cancer development and metastasis in transgenic mouse model of prostate adenocarcinoma. Cancer Res. 2011, 71, 2318–2327. [CrossRef] [PubMed]
267. Brzozowa, M.; Wyrobiec, G.; Kołodziej, I.; Sitarski, M.; Matysiak, N.; Reichman-Warmusz, E.; Żaba, M.; Wojnicz, R. The aberrant overexpression of vimentin is linked to a more aggressive status in tumours of the gastrointestinal tract. Gastroenterol. Rev. 2015, 1, 7–11. [CrossRef] [PubMed]
268. Jin, H.; Kawasaki, H.; Hakamada, K.; Kijima, H. Vimentin expression of esophageal squamous cell carcinoma and its aggressive potential for lymph node metastasis. J. Clin. Oncol. 2011, 29, e14566. [CrossRef]
269. Shirahata, A.; Sakata, M.; Sakuraba, K.; Goto, T.; Mizukami, H.; Saito, M.; Ishibashi, K.; Kigawa, G.; Nemoto, H.; Sanada, Y.; et al. Vimentin methylation as a marker for advanced colorectal carcinoma. Anticancer Res. 2009, 29, 279–281. [PubMed]
270. Zou, H.; Harrington, J.; Rego, R.L.; Ahlquist, D.A. A novel method to capture methylated human DNA from stool: Implications for colorectal cancer screening. Clin. Chem. 2007, 53, 1646–1651. [CrossRef] [PubMed]
271. Chen, W.-D.; Han, Z.J.; Skoletsky, J.; Olson, J.; Sah, J.; Myeroff, L.; Platzer, P.; Lu, S.; Dawson, D.; Willis, J.; et al. Detection in Fecal DNA of Colon Cancer–Specific Methylation of the Nonexpressed Vimentin Gene. J. Natl. Cancer Inst. 2005, 97, 1124–1132. [CrossRef] [PubMed]
272. Takemura, K.; Hirayama, R.; Hirokawa, K.; Inagaki, M.; Tsujimura, K.; Esaki, Y.; Mishima, Y. Expression of vimentin in gastric cancer: A possible indicator for prognosis. Pathobiology 1994, 62, 149–154. [CrossRef] [PubMed]
273. Fuyuhiro, Y.; Yashiro, M.; Noda, S.; Kashiwagi, S.; Matsuoka, J.; Doi, Y.; Kato, Y.; Kubo, N.; Ohira, M.; Hirakawa, K. Clinical significance of vimentin-positive gastric cancer cells. Anticancer Res. 2010, 30, 5239–5243. [PubMed]
274. Gustmann, C.; Altmannsberger, M.; Osborn, M.; Griesser, H.; Feller, A.C. Cytokeratin expression and vimentin content in large cell anaplastic lymphomas and other non-Hodgkin’s lymphomas. Am. J. Pathol. 1991, 138, 1413–1422. [PubMed]
275. Coppola, D.; Fu, L.; Nicosia, S.V.; Kounelis, S.; Jones, M. Prognostic significance of p53, bcl-2, vimentin, and S 100 protein-positive langerhans cells in endometrial carcinoma. Hum. Pathol. 1998, 29, 455–462. [CrossRef]
276. Yamamoto, Y.; Izumi, K.; Otsuka, H. An immunohistochemical study of epithelial membrane antigen, cytokeratin, and vimentin in papillary thyroid carcinoma. Recognition of lethal and favorable prognostic types. Cancer 1992, 70, 2326–2333. [CrossRef]
277. Gilles, C.; Polette, M.; Piette, J.; Delvigne, A.C.; Thompson, E.W.; Foidart, J.-M.; Birembaut, P. Vimentin expression in cervical carcinomas: Association with invasive and migratory potential. J. Pathol. 1996, 180, 175–180. [CrossRef]
278. Williams, A.A.; Higgins, J.P.; Zhao, H.; Ljungberg, B.; Brooks, J.D. CD 9 and vimentin distinguish clear cell from chromophobe renal cell carcinoma. BMC Clin. Pathol. 2009, 9, 9. [CrossRef] [PubMed]
279. Yamada, T.; Kawamata, T.; Walker, D.G.; McGeer, P.L. Vimentin immunoreactivity in normal and pathological human brain tissue. Acta Neuropathol. 1992, 84, 157–162. [CrossRef] [PubMed]
280. Trog, D.; Yeghiazaryan, K.; Schild, H.H.; Golubnitschaja, O. Up-regulation of vimentin expression in low-density malignant glioma cells as immediate and late effects under irradiation and temozolomide treatment. Amino Acids 2007, 34, 539–545. [CrossRef] [PubMed]
281. FitzGerald, P.G. Lens intermediate filaments. Exp. Eye Res. 2009, 88, 165–172. [CrossRef] [PubMed]
282. Joo, C.-K.; Lee, E.H.; Kim, J.-C.; Kim, Y.-H.; Lee, J.-H.; Kim, J.-T.; Chung, K.-H.; Kim, J. Degeneration and transdifferentiation of human lens epithelial cells in nuclear and anterior polar cataracts. J. Cataract Refract. Surg. 1999, 25, 652–658. [CrossRef]
283. Zhang, L.; Wang, Y.; Li, W.; Tsonis, P.A.; Li, Z.; Xie, L.; Huang, Y. MicroRNA-30a Regulation of Epithelial-Mesenchymal Transition in Diabetic Cataracts Through Targeting SNAI1. Sci. Rep. 2017, 7, 614. [CrossRef] [PubMed]
284. Mortensen, J.H.; Godskesen, L.E.; Jensen, M.D.; Van Haaften, W.T.; Klinge, L.G.; Olinga, P.; Dijkstra, G.; Kjeldsen, J.; Karsdal, M.A.; Bay-Jensen, A.-C.; et al. Fragments of Citrullinated and MMP-degraded Vimentin and MMP-degraded Type III Collagen Are Novel Serological Biomarkers to Differentiate Crohn’s Disease from Ulcerative Colitis. J. Crohn’s Colitis 2015, 9, 863–872. [CrossRef] [PubMed]
285. Stevens, C.; Henderson, P.; Nimmo, E.R.; Soares, D.C.; Dogan, B.; Simpson, K.W.; Barrett, J.C. International Inflammatory Bowel Disease Genetics Consortium; Wilson, D.C.; Satsangi, J. The intermediate filament protein, vimentin, is a regulator of NOD2 activity. Gut 2013, 62, 695–707. [CrossRef] [PubMed]
286. Flier, S.N.; Tanjore, H.; Kokkotou, E.G.; Sugimoto, H.; Zeisberg, M.; Kalluri, R. Identification of epithelial to mesenchymal transition as a novel source of fibroblasts in intestinal fibrosis. J. Biol. Chem. 2010, 285, 20202–20212. [CrossRef] [PubMed]
287. Scharl, M.; Huber, N.; Lang, S.; Fürst, A.; Jehle, E.; Rogler, G. Hallmarks of epithelial to mesenchymal transition are detectable in Crohn’s disease associated intestinal fibrosis. Clin. Transl. Med. 2015, 4, 244. [CrossRef] [PubMed]
288. Steenvoorden, M.M.C.; Tolboom, T.C.A.; van der Pluijm, G.; Löwik, C.; Visser, C.P.J.; DeGroot, J.; Gittenberger-DeGroot, A.C.; DeRuiter, M.C.; Wisse, B.J.; Huizinga, T.W.J.; et al. Transition of healthy to diseased synovial tissue in rheumatoid arthritis is associated with gain of mesenchymal/fibrotic characteristics. Arthritis Res. Ther. 2006, 8, R165. [CrossRef] [PubMed]
289. Roland, P.N.; Mignot, S.G.; Bruns, A.; Hurtado, M.; Palazzo, E.; Hayem, G.; Dieudé, P.; Meyer, O.; Martin, S.C. Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy. Arthritis Res. Ther. 2008, 10, R142. [CrossRef] [PubMed]
290. Mathsson, L.; Mullazehi, M.; Wick, M.C.; Sjöberg, O.; van Vollenhoven, R.; Klareskog, L.; Rönnelid, J. Antibodies against citrullinated vimentin in rheumatoid arthritis: Higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis Rheum. 2007, 58, 36–45. [CrossRef] [PubMed]
291. Hill, J.A.; Southwood, S.; Sette, A.; Jevnikar, A.M.; Bell, D.A.; Cairns, E. Cutting edge: The conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J. Immunol. 2003, 171, 538–541. [CrossRef] [PubMed]
292. Bang, H.; Egerer, K.; Gauliard, A.; Lüthke, K.; Rudolph, P.E.; Fredenhagen, G.; Berg, W.; Feist, E.; Burmester, G.-R. Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum. 2007, 56, 2503–2511. [CrossRef] [PubMed]
293. Fernández-Ortega, C.; Dubed, M.; Ramos, Y.; Navea, L.; Alvarez, G.; Lobaina, L.; López, L.; Casillas, D.; Rodríguez, L. Non-induced leukocyte extract reduces HIV replication and TNF secretion. Biochem. Biophys. Res. Commun. 2004, 325, 1075–1081. [CrossRef] [PubMed]
294. Saito, A. EMT and EndMT: Regulated in similar ways? J. Biochem. 2013, 153, 493–495. [CrossRef] [PubMed]
295. Kovacic, J.C.; Mercader, N.; Torres, M.; Boehm, M.; Fuster, V. Epithelial-to-mesenchymal and endothelial-to-mesenchymal transition: From cardiovascular development to disease. Circulation 2012, 125, 1795–1808. [CrossRef] [PubMed]
296. Evrard, S.M.; Lecce, L.; Michelis, K.C.; Nomura-Kitabayashi, A.; Pandey, G.; Purushothaman, K.-R.; d’Escamard, V.; Li, J.R.; Hadri, L.; Fujitani, K.; et al. Endothelial to mesenchymal transition is common in atherosclerotic lesions and is associated with plaque instability. Nat. Commun. 2016, 7, 11853. [CrossRef] [PubMed]
297. Margadant, C.; Sonnenberg, A. Integrin-TGF-beta crosstalk in fibrosis, cancer and wound healing. EMBO Rep. 2010, 11, 97–105. [CrossRef] [PubMed]
298. Matsuyama, M.; Tanaka, H.; Inoko, A.; Goto, H.; Yonemura, S.; Kobori, K.; Hayashi, Y.; Kondo, E.; Itohara, S.; Izawa, I.; et al. Defect of mitotic vimentin phosphorylation causes microophthalmia and cataract via aneuploidy and senescence in lens epithelial cells. J. Biol. Chem. 2013, 288, 35626–35635. [CrossRef] [PubMed]
299. Menko, A.S.; Bleaken, B.M.; Libowitz, A.A.; Zhang, L.; Stepp, M.A.; Walker, J.L. A central role for vimentin in regulating repair function during healing of the lens epithelium. Mol. Biol. Cell 2014, 25, 776–790. [CrossRef] [PubMed]
300. Misra, A.K.; Menon, N.K.; Mishra, S.K. Abnormal distribution of desmin and vimentin in myofibers in adult onset myotubular myopathy. Muscle Nerve 1992, 15, 1246–1252. [CrossRef] [PubMed]
301. Sarnat, H.B. Vimentin and desmin in maturing skeletal muscle and developmental myopathies. Neurology 1992, 42, 1616–1624. [CrossRef] [PubMed]
302. Bornemann, A.; Schmalbruch, H. Anti-vimentin staining in muscle pathology. Neuropathol. Appl. Neurobiol. 1993, 19, 414–419. [CrossRef] [PubMed]
303. Frescas, D.; Roux, C.M.; Aygun-Sunar, S.; Gleiberman, A.S.; Krasnov, P.; Kurnasov, O.V.; Strom, E.; Virtuoso, L.P.; Wrobel, M.; Osterman, A.L.; et al. Senescent cells expose and secrete an oxidized form of membrane-bound vimentin as revealed by a natural polyreactive antibody. Proc. Natl. Acad. Sci. USA 2017, 114, E1668–E1677. [CrossRef] [PubMed]
304. Tanaka, H.; Goto, H.; Inoko, A.; Makihara, H.; Enomoto, A.; Horimoto, K.; Matsuyama, M.; Kurita, K.; Izawa, I.; Inagaki, M. Cytokinetic Failure-induced Tetraploidy Develops into Aneuploidy, Triggering Skin Aging in Phosphovimentin-deficient Mice. J. Biol. Chem. 2015, 290, 12984–12998. [CrossRef] [PubMed]
305. Bargagna-Mohan, P.; Hamza, A.; Kim, Y.; Khuan Abby Ho, Y.; Mor-Vaknin, N.; Wendschlag, N.; Liu, J.; Evans, R.M.; Markovitz, D.M.; Zhan, C.-G.; et al. The Tumor Inhibitor and Antiangiogenic Agent Withaferin A Targets the Intermediate Filament Protein Vimentin. Chem. Biol. 2007, 14, 623–634. [CrossRef] [PubMed]
306. Mohan, R.; Hammers, H.; Bargagna-Mohan, P.; Zhan, X.; Herbstritt, C.; Ruiz, A.; Zhang, L.; Hanson, A.; Conner, B.; Rougas, J.; et al. Withaferin A is a potent inhibitor of angiogenesis. Angiogenesis 2004, 7, 115–122. [CrossRef] [PubMed]
307. Lahat, G.; Zhu, Q.-S.; Huang, K.-L.; Wang, S.; Bolshakov, S.; Liu, J.; Torres, K.; Langley, R.R.; Lazar, A.J.; Hung, M.C.; et al. Vimentin Is a Novel Anti-Cancer Therapeutic Target; Insights from In Vitro and In Vivo Mice Xenograft Studies. PLoS ONE 2010, 5, e10105. [CrossRef] [PubMed]
308. Thaiparambil, J.T.; Bender, L.; Ganesh, T.; Kline, E.; Patel, P.; Liu, Y.; Tighiouart, M.; Vertino, P.M.; Harvey, R.D.; Garcia, A.; et al. Withaferin A inhibits breast cancer invasion and metastasis at sub-cytotoxic doses by inducing vimentin disassembly and serine 56 phosphorylation. Int. J. Cancer 2011, 129, 2744–2755. [CrossRef] [PubMed]
309. Munagala, R.; Kausar, H.; Munjal, C.; Gupta, R.C. Withaferin A induces p53-dependent apoptosis by repression of HPV oncogenes and upregulation of tumor suppressor proteins in human cervical cancer cells. Carcinogenesis 2011, 32, 1697–1705. [CrossRef] [PubMed]
310. Yu, Y.; Hamza, A.; Zhang, T.; Gu, M.; Zou, P.; Newman, B.; Li, Y.; Gunatilaka, A.A.L.; Zhan, C.-G.; Sun, D. Withaferin A targets heat shock protein 90 in pancreatic cancer cells. Biochem. Pharmacol. 2010, 79, 542–551. [CrossRef] [PubMed]
311. Burikhanov, R.; Sviripa, V.M.; Hebbar, N.; Zhang, W.; Layton, W.J.; Hamza, A.; Zhan, C.-G.; Watt, D.S.; Liu, C.; Rangnekar, V.M. Arylquins target vimentin to trigger Par-4 secretion for tumor cell apoptosis. Nat. Chem. Biol. 2014, 10, 924–926. [CrossRef] [PubMed]
312. Wu, K.; Zeng, J.; Zhu, G.; Zhang, L.; Zhang, D.; Li, L.; Fan, J.; Wang, X.; He, D. Silibinin inhibits prostate cancer invasion, motility and migration by suppressing vimentin and MMP-2 expression. Acta Pharmacol. Sin. 2009, 30, 1162–1168. [CrossRef] [PubMed]
313. Singh, R.P.; Raina, K.; Sharma, G.; Agarwal, R. Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice. Clin. Cancer Res. 2008, 14, 7773–7780. [CrossRef] [PubMed]
314. Nambiar, D.K.; Rajamani, P.; Singh, R.P. Silibinin attenuates ionizing radiation-induced pro-angiogenic response and EMT in prostate cancer cells. Biochem. Biophys. Res. Commun. 2015, 456, 262–268. [CrossRef] [PubMed]
315. Prajapati, V.; Kale, R.K.; Singh, R.P. Silibinin Combination with Arsenic Strongly Inhibits Survival and Invasiveness of Human Prostate Carcinoma Cells. Nutr. Cancer 2015, 67, 647–658. [CrossRef] [PubMed]
316. Dong, T.-T.; Zhou, H.-M.; Wang, L.-L.; Feng, B.; Lv, B.; Zheng, M.-H. Salinomycin Selectively Targets ‘CD133+’ Cell Subpopulations and Decreases Malignant Traits in Colorectal Cancer Lines. Ann. Surg. Oncol. 2011, 18, 1797–1804. [CrossRef] [PubMed]
317. Zamay, T.N.; Kolovskaya, O.S.; Glazyrin, Y.E.; Zamay, G.S.; Kuznetsova, S.A.; Spivak, E.A.; Wehbe, M.; Savitskaya, A.G.; Zubkova, O.A.; Kadkina, A.; et al. DNA-aptamer targeting vimentin for tumor therapy in vivo. Nucleic Acid Ther. 2014, 24, 160–170. [CrossRef] [PubMed]
318. Bollong, M.J.; Pietilä, M.; Pearson, A.D.; Sarkar, T.R.; Ahmad, I.; Soundararajan, R.; Lyssiotis, C.A.; Mani, S.A.; Schultz, P.G.; Lairson, L.L. A vimentin binding small molecule leads to mitotic disruption in mesenchymal cancers. Proc. Natl. Acad. Sci. USA 2017, 114, E9903–E9912. [CrossRef] [PubMed]
319. Noh, H.; Yan, J.; Hong, S.; Kong, L.-Y.; Gabrusiewicz, K.; Xia, X.; Heimberger, A.B.; Li, S. Discovery of cell surface vimentin targeting mAb for direct disruption of GBM tumor initiating cells. Oncotarget 2016, 7, 72021–72032. [CrossRef] [PubMed]
320. Cutrera, J.; Dibra, D.; Xia, X.; Hasan, A.; Reed, S.; Li, S. Discovery of a linear peptide for improving tumor targeting of gene products and treatment of distal tumors by IL-12 gene therapy. Mol. Ther. 2011, 19, 1468–1477. [CrossRef] [PubMed]
321. Trogden, K.P.; Kabiraj, P.; Snider, N.T. The intermediate filament cytoskeleton is a target of statins and statin-induced cancer cell death. FASEB J. 2016, 30, 969–974.
322. Trogden, K.P.; Battaglia, R.A.; Kabiraj, P.; Madden, V.J.; Herrmann, H.; Snider, N.T. An image-based small-molecule screen identifies vimentin as a pharmacologically relevant target of simvastatin in cancer cells. FASEB J. 2018, 32, 2841–2854. [CrossRef] [PubMed]
323. Kanugula, A.K.; Dhople, V.M.; Völker, U.; Ummanni, R.; Kotamraju, S. Fluvastatin Mediated Breast Cancer Cell Death: A Proteomic Approach to Identify Differentially Regulated Proteins in MDA-MB-231 Cells. PLoS ONE 2014, 9, e108890. [CrossRef] [PubMed]
324. Sanghvi-Shah, R.; Weber, G.F. Intermediate Filaments at the Junction of Mechanotransduction, Migration, and Development. Front. Cell Dev. Biol. 2017, 5, 81. [CrossRef] [PubMed]
325. Dobzhansky, T. Nothing in Biology Makes Sense except in the Light of Evolution. Am. Biol. Teach. 1973, 35, 125–129. [CrossRef]